Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;13(1):1101-1110.
doi: 10.1080/21505594.2022.2092941.

The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets

Jianli Ma  1 , Yuwei Deng  2 , Minghui Zhang  3 , Jinming Yu  1
Affiliations
Review

The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets

Jianli Ma et al. Virulence. 2022 Dec.

Abstract

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, has led to more than 170 million confirmed cases in 223 countries and regions, claiming 3,872,457 lives. Some patients with COVID-19 have mild clinical symptoms despite severe respiratory failure, which greatly increases the difficulty of diagnosis and treatment. It is therefore necessary to identify biological characteristics of SARS-CoV-2, screen novel diagnostic and prognostic biomarkers, as well as to explore potential therapeutic targets for COVID-19. In this comprehensive review, we discuss the current published literature on COVID-19. We find that the comprehensive application of genomics, transcriptomics, proteomics and metabolomics is becoming increasingly important in the treatment of COVID-19. Multi-omics analysis platforms are expected to revolutionize the diagnosis and classification of COVID-19. This review aims to provide a reference for diagnosis, surveillance and clinical decision making related to COVID-19.

Keywords: COVID-19; genomics; metabolomics; multi-omics; proteomics; transcriptomic.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Similar articles

See all similar articles

Cited by

References

    1. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. DOI:10.1001/jama.2020.12839 - DOI - PubMed
    1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio....
    1. Vkovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170. DOI:10.1038/s41579-020-00468-6 - DOI - PMC - PubMed
    1. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting enzyme 2: SARS-CoV-2 receptor and regulator of the Renin-Angiotensin system: celebrating the 20th Anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474. DOI:10.1161/CIRCRESAHA.120.317015 - DOI - PMC - PubMed
    1. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with Tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181:41–51. - PMC - PubMed

Publication types